Luminex has patented methods and compositions for nucleic acid amplification, detection, and genotyping. The patent includes a method for amplifying a target nucleic acid using specific primers, a reporter, and a capture complex. This innovation enhances nucleic acid analysis techniques. GlobalData’s report on Luminex gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Luminex Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Luminex, was a key innovation area identified from patents. Luminex's grant share as of February 2024 was 100%. Grant share is based on the ratio of number of grants to total number of patents.

Nucleic acid amplification method using specific primers and blockers

Source: United States Patent and Trademark Office (USPTO). Credit: Luminex Corp

A recently granted patent (Publication Number: US11884965B2) discloses a method for amplifying a target nucleic acid using a unique primer pair, a reporter, and a capture complex attached to a solid support. The method involves providing a first primer pair with specific sequences, a reporter, and a capture complex with an anti-tag sequence on a solid support. The target nucleic acid is then amplified by combining these components with a sample containing the target nucleic acid under suitable conditions for amplification.

Furthermore, the method includes hybridizing the amplified nucleic acid to the anti-tag sequence of the capture complex, attaching the reporter to the second primer, and using a DNA intercalator as the reporter. The solid support used can be a microsphere, which may be magnetic and fluorescently labeled. The amplification process is catalyzed by a polymerase with strand displacement activity but without exonuclease activity. Additionally, the method allows for the detection of the amplified nucleic acid, including imaging the amplified target nucleic acid sequence bound to the capture complex. The patent also covers scenarios where multiple target nucleic acids are present in the sample, requiring the combination of different primer pairs, reporters, and capture complexes for their amplification and detection, with the ability to distinguish between different amplified target nucleic acids using spatially or optically distinguishable capture complexes.

To know more about GlobalData’s detailed insights on Luminex, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.